These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35764510)

  • 1. Modulation, microbiota and inflammation in the adult CF gut: A prospective study.
    Ronan NJ; Einarsson GG; Deane J; Fouhy F; Rea M; Hill C; Shanahan F; Elborn JS; Ross RP; McCarthy M; Murphy DM; Eustace JA; Mm T; Stanton C; Plant BJ
    J Cyst Fibros; 2022 Sep; 21(5):837-843. PubMed ID: 35764510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
    Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation.
    Ooi CY; Syed SA; Rossi L; Garg M; Needham B; Avolio J; Young K; Surette MG; Gonska T
    Sci Rep; 2018 Dec; 8(1):17834. PubMed ID: 30546102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor.
    Einarsson GG; Ronan NJ; Mooney D; McGettigan C; Mullane D; NiChroinin M; Shanahan F; Murphy DM; McCarthy M; McCarthy Y; Eustace JA; Gilpin DF; Elborn JS; Plant BJ; Tunney MM
    J Cyst Fibros; 2021 Sep; 20(5):747-753. PubMed ID: 33549519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.
    Hoppe JE; Wagner BD; Kirk Harris J; Rowe SM; Heltshe SL; DeBoer EM; Sagel SD
    J Cyst Fibros; 2022 Nov; 21(6):950-958. PubMed ID: 35440409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
    PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
    Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
    J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
    McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
    Zhang S; Shrestha CL; Kopp BT
    Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
    Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
    Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
    Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
    J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.